Moderna, Inc. vs SPDR Kensho Final Frontiers ETF — how do they compare? Moderna, Inc. trades at $135.9 (market cap $56.02B), while SPDR Kensho Final Frontiers ETF trades at $106.56. The key difference: Moderna, Inc. is trading nearer its 52-week high, SPDR Kensho Final Frontiers ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | ROKT | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | Sector/Thematic |
52-Week High | $174.38 | $136.68 |
52-Week Low | $22.36 | $71.62 |
Enterprise Value | $52.17B | — |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
No Aura AI signal available yet.
Trailing returns across standard periods
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →